Analyst consensus rating
BridgeBio Oncology Therapeutics Analyst Rating: Strong Buy
BBOT is rated Strong Buy by 10 analysts with a $24.90 target. As of 2026-08-19.
Direct answer
BridgeBio Oncology Therapeutics's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $24.90.
Forecast evidence checked August 19, 2026.
Get free BridgeBio Oncology Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $8.95
- Average price target
- $24.90
- High price target
- $39.00
- Low price target
- $18.00
- Low target gap
- +101.1%
- Target upside
- +178.2%
- High target gap
- +335.8%
- Target range width
- 234.6%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $24.90.
How far are BridgeBio Oncology Therapeutics's low and high targets from the recorded price?
The low target implies +101.1%, while the high target implies +335.8%.
How many analysts are included in BridgeBio Oncology Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is BridgeBio Oncology Therapeutics's target upside or downside calculated?
The average target of $24.90 is divided by the recorded price of $8.95, then one is subtracted to produce +178.2%. This does not guarantee a future return.
When was BridgeBio Oncology Therapeutics's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.